Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;3(2):e91.
doi: 10.1016/S2666-5247(21)00278-0. Epub 2021 Nov 25.

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era

Huahao Fan  1 , Fuxing Lou  1 , Junfen Fan  2 , Maochen Li  1 , Yigang Tong  1
Affiliations

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era

Huahao Fan et al. Lancet Microbe. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This research was supported by the Key Project of Beijing University of Chemical Technology (grant number XK1803-06), the National Key Research and Development Program of China (grant numbers 2018YFA0903000, 2020YFC2005405, 2020YFA0712100, 2020YFC0840805), the Funds for First-class Discipline Construction (grant number XK1805), the Inner Mongolia Key Research and Development Program (grant number 2019ZD006), the National Natural Science Foundation of China (grant numbers 81672001, 81621005), the NSFC-MFST project (China-Mongolia) (grant number 31961143024), and the Fundamental Research Funds for Central Universities (grant numbers BUCTRC201917, BUCTZY2022). HF, FL, JF, and ML contributed equally. We declare no competing interests.

References

    1. Schooley RT, Carlin AF, Beadle JR, et al. Rethinking remdesivir: synthesis, antiviral activity and pharmacokinetics of oral lipid prodrugs. bioRxiv. 2021 doi: 10.1101/2020.08.26.269159. published online June 7. (preprint). - DOI - PMC - PubMed
    1. Malone B, Campbell EA. Molnupiravir: coding for catastrophe. Nat Struct Mol Biol. 2021;28:706–708. - PubMed
    1. Merck Merck and Ridgeback's investigational oral antiviral molnupiravir reduced the risk of hospitalisation or death by approximately 50 percent compared to placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study. Oct 1, 2021. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-ant...
    1. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12 - PMC - PubMed
    1. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021 doi: 10.1101/2021.06.17.21258639. published online June 17. (preprint). - DOI

Publication types